nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Addendum 6: A few key elements in the design and interpretation of pharmaco-epidemiological studies
|
|
|
2013 |
|
2-3 |
p. 251-261 |
artikel |
2 |
Addendum 4: British guidelines for “postmarketing surveillance studies”
|
|
|
2013 |
|
2-3 |
p. 239-241 |
artikel |
3 |
Addendum 7: Glossary and abbreviations
|
|
|
2013 |
|
2-3 |
p. 263-270 |
artikel |
4 |
Addendum 1: Health authorities' ADE reporting forms
|
|
|
2013 |
|
2-3 |
p. 223-225 |
artikel |
5 |
Addendum 2: Reporting ADEs to health authorities
|
|
|
2013 |
|
2-3 |
p. 227-230 |
artikel |
6 |
Addendum 3: Screening ADE databases
|
|
|
2013 |
|
2-3 |
p. 231-237 |
artikel |
7 |
Addendum 5: Useful databases
|
|
|
2013 |
|
2-3 |
p. 243-250 |
artikel |
8 |
Analysis of the information in a central ADE database
|
|
|
2013 |
|
2-3 |
p. 105-123 |
artikel |
9 |
A presentation of compulsory licensing
|
James Love |
|
2001 |
|
2-3 |
p. 153-161 |
artikel |
10 |
Book reviews
|
|
|
2001 |
|
2-3 |
p. 187-190 |
artikel |
11 |
Britain's rising caesarean rate: Time to take action
|
Tara Kaufmann |
|
2001 |
|
2-3 |
p. 103-107 |
artikel |
12 |
Causality assessment of individual ADEs
|
|
|
2013 |
|
2-3 |
p. 125-144 |
artikel |
13 |
Concerns about the use of buspirone in Alzheimer patients
|
Ian Williams Goddard |
|
2001 |
|
2-3 |
p. 91-94 |
artikel |
14 |
Consumer reports on medicines?–?CRM: Policy and Practice
|
|
|
2001 |
|
2-3 |
p. 117-127 |
artikel |
15 |
Dying of market failure
|
Ellen 't Hoen |
|
2001 |
|
2-3 |
p. 137-142 |
artikel |
16 |
Early failure and mortality following intramedullary fixation of peritrochanteric fractures
|
N. Levi |
|
2001 |
|
2-3 |
p. 99-101 |
artikel |
17 |
East Timor: Building health in a vacuum
|
|
|
2001 |
|
2-3 |
p. 177-178 |
artikel |
18 |
Electrical safety in patient care areas
|
Cislo, Ray |
|
2013 |
|
2-3 |
p. 157-159 |
artikel |
19 |
Estimating the frequency of adverse drug effects from spontaneous ADE reports
|
|
|
2013 |
|
2-3 |
p. 145-166 |
artikel |
20 |
Extra-hospital dialysis: the patient is at risk, not the method
|
Viron, B. |
|
2013 |
|
2-3 |
p. 145-155 |
artikel |
21 |
Foreword
|
|
|
2013 |
|
2-3 |
p. 75-76 |
artikel |
22 |
Four editorial proposals to improve social sciences research and publication
|
Jay Joseph |
|
2001 |
|
2-3 |
p. 109-116 |
artikel |
23 |
From knowledge to action: improving drug safety
|
|
|
2013 |
|
2-3 |
p. 195-209 |
artikel |
24 |
Health foods or healthy foodsAthens, 22–24 November 1990
|
|
|
2013 |
|
2-3 |
p. 161-164 |
artikel |
25 |
Hippocrates
|
|
|
2001 |
|
2-3 |
p. 183-185 |
artikel |
26 |
Information for Authors
|
|
|
2013 |
|
2-3 |
p. 169-170 |
artikel |
27 |
Interactions between herbal medicinal products and synthetic drugs
|
|
|
2001 |
|
2-3 |
p. 77-79 |
artikel |
28 |
IntroductionPharmacovigilance: what is it? why does it exist?
|
|
|
2013 |
|
2-3 |
p. 77-84 |
artikel |
29 |
Is risk management necessary?
|
Dingwall, Robert |
|
2013 |
|
2-3 |
p. 91-106 |
artikel |
30 |
Legal implications of discrimination in medical practice
|
Jessamyn S. Berniker |
|
2001 |
|
2-3 |
p. 129-133 |
artikel |
31 |
Norway: Patient Compensation Council
|
|
|
2001 |
|
2-3 |
p. 179-181 |
artikel |
32 |
Oslo statement
|
|
|
2001 |
|
2-3 |
p. 175-176 |
artikel |
33 |
Patient rights versus patent rights
|
|
|
2001 |
|
2-3 |
p. 135-136 |
artikel |
34 |
Patient versus patent rights
|
Zweli Mkhize |
|
2001 |
|
2-3 |
p. 167-173 |
artikel |
35 |
Pharmaco-epidemiological approaches to the study of signals
|
|
|
2013 |
|
2-3 |
p. 167-193 |
artikel |
36 |
Prescription drugs: Direct advertising?
|
|
|
2001 |
|
2-3 |
p. 81-86 |
artikel |
37 |
Prices and access to essential medicines
|
Carl-Erik Schulz |
|
2001 |
|
2-3 |
p. 143-151 |
artikel |
38 |
Psychiatric drugs for infants and toddlers: Treatment or crime?
|
|
|
2001 |
|
2-3 |
p. 87-90 |
artikel |
39 |
Reviews of books and studies
|
|
|
2013 |
|
2-3 |
p. 165-167 |
artikel |
40 |
Risk management: a practical approach
|
|
|
2013 |
|
2-3 |
p. 63 |
artikel |
41 |
Risk management implementation programmes
|
Roberts, Geoffrey |
|
2013 |
|
2-3 |
p. 141-143 |
artikel |
42 |
Risk management in anaesthesia
|
Aitkenhead, A.R. |
|
2013 |
|
2-3 |
p. 113-123 |
artikel |
43 |
Risk management in obstetrics and gynaecology
|
James, Catherine E. |
|
2013 |
|
2-3 |
p. 133-140 |
artikel |
44 |
Risk management in surgery
|
Smith, Joseph C. |
|
2013 |
|
2-3 |
p. 125-128 |
artikel |
45 |
Risk management in trauma and orthopaedics
|
Vickers, Roger |
|
2013 |
|
2-3 |
p. 107-111 |
artikel |
46 |
Safety and risk in practice
|
|
|
2001 |
|
2-3 |
p. 191-193 |
artikel |
47 |
Screening for human T-cell lymphotrophic virus type I (HTLV-I) infection in Jewish psychiatric patients of Iranian origin
|
B. Spivak |
|
2001 |
|
2-3 |
p. 95-98 |
artikel |
48 |
Signal detection by spontaneous reporting
|
|
|
2013 |
|
2-3 |
p. 91-104 |
artikel |
49 |
The drug safety crisis
|
|
|
2013 |
|
2-3 |
p. 211-222 |
artikel |
50 |
The Finnish patient insurance and compensation scheme
|
|
|
2001 |
|
2-3 |
p. 195-197 |
artikel |
51 |
The physician's civil liability under Danish law
|
Fenger, Niels |
|
2013 |
|
2-3 |
p. 65-82 |
artikel |
52 |
The risks of obstetrics and gynaecology in practice
|
Chamberlain, Geoffrey |
|
2013 |
|
2-3 |
p. 129-132 |
artikel |
53 |
Unaffordable medicine pricing: Brazil's experience
|
Maria Fernanda Macedo |
|
2001 |
|
2-3 |
p. 163-166 |
artikel |
54 |
Unwanted outcomes of drug treatment and their study
|
|
|
2013 |
|
2-3 |
p. 85-89 |
artikel |
55 |
What is risk management?
|
Hill, Garth |
|
2013 |
|
2-3 |
p. 83-90 |
artikel |